ABO-Incompatible Living Kidney Transplant Recipients from Spousal Donors Receiving Rituximab.

Abstract

INTRODUCTION:

We summarized our experience with ABO-incompatible living kidney transplant recipients from spousal donors receiving rituximab.

PATIENTS AND METHODS:

Between June 2006 and December 2014, 82 patients with end-stage renal disease underwent living donor kidney transplantation at Osaka City University Hospital, of which 23 cases were ABO-incompatible transplantation between spouses with rituximab induction. We analyzed these recipients, focusing on their immunosuppressive protocols, frequency of acute rejections, and patient/graft survivals.

RESULTS:

Patient and graft survival rates were 100%. The incidence of acute cellular rejection (ACR) was 30.4%. One patient experienced antibody-mediated rejection (AMR) and intractable ACR, 2 had AMR, and 2 had intractable ACR episodes that were treated using thymoglobulin.

CONCLUSIONS:

This study demonstrated that ABO-incompatible kidney transplantation between spouses using rituximab is a radical but effective treatment for end-stage renal disease. However, this procedure could be immunologically high risk due to ABO-incompatibility and poor histocompatibility.

• Authors: Junji Uchida, Tomoaki Iwai, Kazuya Kabei, Shunji Nishide, Takeshi Yamasaki, Nobuyuki Kuwabara, Toshihide Naganuma, Norihiko Kumada, Yoshiaki Takemoto, Tatsuya Nakatanti
• Journal: Urologia internationalis (Urol Int) Vol. 97 Issue 4 Pg. 457-465 ( 2016) ISSN: 1423-0399 [Electronic] Switzerland
• PMID: 27732972 (Publication Type: Journal Article)
• Copyright: © 2016 S. Karger AG, Basel.

Chemical References

• ABO Blood-Group System
• Immunosuppressive Agents
• Rituximab

Topics

• ABO Blood-Group System
• Blood Group Incompatibility
• Graft Rejection
• Graft Survival
• Humans
• Immunosuppressive Agents
• Kidney Transplantation
• Living Donors
• Rituximab
• Treatment Outcome